Fremanezumab autoinjector pen for the prevention of migraine.
Fremanezumab autoinjector pen for the prevention of migraine.
复制标题
用于预防偏头痛的 Fremanezumab 自动注射笔。
DOI：
10.4155/tde-2021-0028
复制
发表时间：
2021
影响因子：
4.2
通讯作者：
M. Weatherall
中科院分区：
文献类型：
--
作者：
M. Weatherall
Ajovy (fremanezumab, Teva Pharmaceuticals, Israel) is a fully humanized monoclonal antibody that selectively binds both isoforms of the calcitonin gene-related peptide. Calcitonin gene-related peptide is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events in migraine. It is indicated for prophylaxis of migraine in adults who have at least four migraine days per month, and can be administered as a subcutaneous injection using an autoinjector device, with two dosing options: 225 mg once a month or 675 mg quarterly. In this article, I present data from Phase III clinical trials of fremanezumab in episodic and chronic migraine, in which fremanezumab demonstrated efficacy and had a favorable tolerability profile, with no serious treatment-related adverse events.
